VanEck Pharmaceutical ETF

PPH

Market cap $627M

Overview Fund Activity

89.07 USD

-1.05

1.17%

At close Updated Sep 12, 4:00 PM EDT

1 day

-1.17%

5 days

0.41%

1 month

6.59%

3 months

-2.95%

6 months

-2.66%

Year to date

3.16%

1 year

-8.46%

5 years

42.22%

10 years

32.52%

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

35.29% more ownership

Funds ownership: 78.06% [Q1] → 113.35% (+35.29%) [Q2]

27% more capital invested

Capital invested by funds: $529M [Q1] → $672M (+$142M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

10% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 42

5% less funds holding

Funds holding: 132 [Q1] → 125 (-7) [Q2]

22% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 23

92% less call options, than puts

Call options by funds: $3.32M | Put options by funds: $41.4M

See Fund Rankings

Financial journalist opinion

Zacks Investment Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on 12/20/2011.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

PPH: Global Pharma Stocks Continue To Face Headwinds, Tariffs Front And Center

I maintain a hold rating on PPH due to attractive valuation but weak technical momentum and underperformance versus the S&P 500. Eli Lilly and Johnson & Johnson, PPH's largest holdings, are facing unique challenges, impacting the ETF's overall performance and outlook. Despite a low P/E ratio and solid dividend yield, PPH's concentrated portfolio and poor price action warrant caution for now.

PPH: Global Pharma Stocks Continue To Face Headwinds, Tariffs Front And Center

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Zacks Investment Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

The VanEck Pharmaceutical ETF (PPH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Zacks Investment Research

ETFs on the Move Post U.S.-China Trade Deal

Let's delve into the ETF world following the 90-day U.S.-China trade deal.

ETFs on the Move Post U.S.-China Trade Deal

Zacks Investment Research

A Look at Pharma ETFs After Strong Q1 Earnings

Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Strong Q1 Earnings

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volatility.

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

PPH: Will Overcome Tariffs, But Competitor Funds Look Stronger

VanEck Pharmaceutical ETF holds a mixed outlook due to high fees and tariff risks, warranting a hold rating despite strong top holdings. PPH's top holdings like Eli Lilly and Johnson & Johnson have diversified revenue streams and U.S. manufacturing investments, mitigating tariff impacts. PPH has underperformed compared to broader healthcare ETFs like VHT and XLV, which offer better diversification and lower expense ratios.

PPH: Will Overcome Tariffs, But Competitor Funds Look Stronger

Zacks Investment Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on 12/20/2011.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Seeking Stocks With Vitality In The Volatile Healthcare Sector

See News Rankings

Charts implemented using Lightweight Charts™